Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial

作者：Xiaotian Zhang, Liang Han, Ziyu Li, Yingwei Xue, Yanong Wang, Zhiwei Zhou, Jiren Yu, Zhaode Bu, Lin Chen, Yian Du, Xinbao Wang, Aiwen Wu, Guoli Li, Xiangqian Su, Gang Xiao, Ming Cui, Dan Wu, Li Chen, Xiaojiang Wu, Yanbing Zhou, Lianhai Zhang, Chengxue Dang, Yulong He, Zhongtao Zhang, Yihong Sun, Yong Li, Huanqiu Chen, Yuxian Bai, Yakun Wang, Peiwu Yu, Guanbao Zhu, Jian Suo, Baoqing Jia, Leping Li, Ze-Ning Huang, Fei Li, Yingjiang Ye, Huimian Xu, Xin Wang, Yannan Yuan, E Jian‐Yu, Xiangji Ying, Chen Yao, Lin Shen, Jiafu Ji · 发表于：The Lancet Oncology · 年份：2025 · DOI：10.1016/s1470-2045(24)00676-4 · 被引用次数：53 · 研究领域：Gastric Cancer Management and Outcomes、Esophageal Cancer Research and Treatment、Colorectal Cancer Surgical Treatments